ALX 0646Alternative Names: ALX 646
Latest Information Update: 12 Dec 2003
At a glance
- Originator NPS Allelix
- Class Antimigraines
- Mechanism of Action Serotonin receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Migraine
Most Recent Events
- 12 Dec 2003 Discontinued - Phase-I for Migraine in United Kingdom (PO)
- 12 Mar 2002 Forest returned all rights to ALX 0646 to NPS
- 12 Nov 2001 NPS Allelix has received a milestone payment from Forest